A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Financial Summary
| Share Statistics | NPPNY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,568.6 | $618.0 | 50% |
|
| Shares Out (Mil) | 0.4 | 44.8 | 2% |
|
| Institutional Ownership | 49.8% | 85.3% | 26% |
|
| Float (Mil) | 62.8 | 47.4 | 52% |
|
| Beta | na | 0.70 | na |
|
| Avg Daily Volume (000s) | 0 | 390 | 0% |
|
| Price Change (52-week) |
(54.9%) | 68.6% | 13% |
|
| Growth | NPPNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.5%) | 6.7% | 16% |
|
| Net Income (5yr) | 0.0% | (1.6%) | 40% |
|
| EPS (5yr) | 0.0% | 14.9% | 31 |
|
| Dividends (5yr) | (2.7%) | 0.0% | 75% |
|
| Cash Flow (5yr) | 9.5% | (14.9%) | 69% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NPPNY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,074 | $291 | 51% |
|
| Net Income (TTM) (Mil) | $187 | ($11) | 67% |
|
| EPS (TTM) | $2.774 | ($0.700) | 77% |
|
| Operating Cash Flow (TTM) (Mil) | $171 | ($6) | 57% |
|
| Net Cash Flow (TTM) (Mil) | $159 | $5 | 82% |
|
| Long-Term Debt (Q1) (Mil) | $10 | $6 | 28% |
|
| Enterprise Value (Q1) (Mil) | na | $450 | na |
|
| Valuation | NPPNY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.78 | na |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | NPPNY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | 9.5% | (22.4%) | 86% |
|
| ROE | 11.4% | (20.2%) | 61% |
|
| Liabilities to Assets | 15.7% | 32.2% | 10% |
|
| F-Score | na | 3 | na |
|
Nippon Shinyaku Co., Ltd. did not pass any screens on 8/20/2026.
